Nektar Therapeutics Stock News

Nektar (NKTR) delivered earnings and revenue surprises of 31.94% and 3.22%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Nektar (NKTR) delivered earnings and revenue surprises of 31.94% and 3.22%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 32.35% and 9.90%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Nektar (NKTR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Bristol-Myers (BMY) Q1 earnings might have gained from strong demand for Eliquis and incremental contribution from newer drugs. Operating expenses might have jumped on broader portfolio-related costs.

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Protagonist's Ulcerative Colitis Study Disappoints With Higher Dose Of PN-943 Protagonist Therapeutics

Nektar Therapeutics (NASDAQ: NKTR) announced a new strategic plan to prioritize key research and development efforts and cut 70% of its workforce, including several changes to its executive team. 

The biotech Nektar Therapeutics aims to extend its cash runway after the failure of its cancer drug partnership with Bristol Myers Squibb.

Shares of Nektar Therapeutics NKTR, +3.51% were down 5.7% in premarket trading on Tuesday, the day after the company said it will lay off 70% of its workforce. As of Dec. 31, the company employed 740

SAN FRANCISCO , April 22, 2022 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) will host an analyst and investor conference call with Nektar executives on Monday, April 25, 2022, at 2:00 p.m. Pacifi

Regulatory and pipeline updates from Nektar (NKTR) and Regeneron (REGN) are a few key highlights from the biotech sector during the past week.

Shares of Nektar Therapeutics (NASDAQ: NKTR) have come under pressure after the company “announced the discontinuation of the remaining clinical development programs of bempeg + nivo (Opdivo) in col

The company is throwing in the towel on its lead pipeline program.

Upgrades For PBF Energy Inc (NYSE:PBF), Scotiabank upgraded the previous rating of Sector Underperform to Sector Perform. For the fourth quarter, PBF Energy had an EPS of $1.28, compared to year-ago q

Nektar's (NKTR) lead clinical program, bempeg plus Bristol-Myers' Opdivo, fails in registrational cancer studies. Nektar and Bristol-Myers decide to discontinue all bempeg plus Opdivo development prog